Caroline A. Lamb

Caroline A. Lamb

Auto-generated profile, based on publicly available information

Caroline A. Lamb

Laboratorio de Carcinogénesis Hormonal, Instituto de Biología y Medicina Experimental (IBYME), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Ciudad de Buenos Aires, Argentina

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 October 2022 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
AEAndrés Elía
Andrés Elía
LSLeo Saldain
Leo Saldain
SVSilvia I. Vanzulli
Silvia I. Vanzulli
Luisa A. HelgueroLuisa A. Helguero
Luisa A. Helguero
CLCaroline A. Lamb
Caroline A. Lamb
CLClaudia Lanari
Claudia Lanari
Purpose: Preclinical data suggest that antiprogestins inhibit the growth of luminal breast carcinomas that express higher levels of progesterone receptor isoform A (PRA) than isoform B (PRB). Thus, we designed a presurgical window of opportunity trial to determine the therapeutic effects of mifepristone in patients with breast cancer, based on their high PRA/PRB isoform ratio (MIPRA; NCT02651844). Patients and Methods: Twenty patients with luminal breast carcinomas with PRA/PRB > 1.5 (determined by Western blots), and PR ≥ 50%, naïve from previous treatment, were included for mifepristone treatment (200 mg/day orally; 14 days). Core needle biopsies and surgical samples were formalin fixed for IHC studies, while others were snap-frozen to perform RNA sequencing (RNA-seq), proteomics, and/or Western blot studies. Plasma mifepristone levels were determined using mass spectrometry. The primary endpoint was the comparison of Ki67 expression pretreatment and posttreatment. Results: A 49.62% decrease in Ki67 staining was observed in all surgical specimens compared with baseline (P = 0.0003). Using the prespecified response parameter (30% relative reduction), we identified 14 of 20 responders. Mifepristone induced an increase in tumor-infiltrating lymphocytes; a decrease in hormone receptor and pSer118ER expression; and an increase in calregulin, p21, p15, and activated caspase 3 expression. RNA-seq and proteomic studies identified downregulated pathways related to cell proliferation and upregulated pathways related to immune bioprocesses and extracellular matrix remodeling. Conclusions: Our results support the use of mifepristone in patients with luminal breast cancer with high PRA/PRB ratios. The combined effects of mifepristone and estrogen receptor modulators warrant clinical evaluation to improve endocrine treatment responsiveness in these patients. See related commentary by Ronchi and Brisken, p. 833

1 March 2021 in Cancer Research
Verified
Journal Article
Closed access
PDF file
GSGonzalo R. Sequeira
Gonzalo R. Sequeira
ASAna Sahores
Ana Sahores
TDTomás Dalotto-Moreno
Tomás Dalotto-Moreno
RPRamiro M. Perrotta
Ramiro M. Perrotta
GPGabriela Pataccini
Gabriela Pataccini
CLClaudia Lanari
Claudia Lanari
The role of active antitumor immunity in hormone receptor–positive (HR+) breast cancer has been historically underlooked. The aim of this study was to determine the contribution of the immune system to antiprogestin-induced tumor growth inhibition using a hormone-dependent breast cancer model. BALB/c-GFP+ bone marrow (BM) cells were transplanted into immunodeficient NSG mice to generate an immunocompetent NSG/BM-GFP+ (NSG-R) mouse model. Treatment with the antiprogestin mifepristone (MFP) inhibited growth of 59–2-HI tumors with similar kinetics in both animal models. Interestingly, MFP treatment reshaped the tumor microenvironment, enhancing the production of proinflammatory cytokines and chemokines. Tumors in MFP-treated immunocompetent mice showed increased infiltration of F4/80+ macrophages, natural killer, and CD8 T cells, displaying a central memory phenotype. Mechanistically, MFP induced immunogenic cell death (ICD) in vivo and in vitro, as depicted by the expression and subcellular localization of the alarmins calreticulin and HMGB-1 and the induction of an ICD gene program. Moreover, MFP-treated tumor cells efficiently activated immature dendritic cells, evidenced by enhanced expression of MHC-II and CD86, and induced a memory T-cell response, attenuating tumor onset and growth after re-challenge. Finally, MFP treatment increased the sensitivity of HR+ 59–2-HI tumor to PD-L1 blockade, suggesting that antiprogestins may improve immunotherapy response rates. These results contribute to a better understanding of the mechanisms underlying the antitumor effect of hormonal treatment and the rational design of therapeutic combinations based on endocrine and immunomodulatory agents in HR+ breast cancer. Significance: Antiprogestin therapy induces immunogenic tumor cell death in PRA-overexpressing tumors, eliciting an adaptive immune memory response that protects mice from future tumor recurrence and increases sensitivity to PD-L1 blockade.

29 November 2011 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
JCJuan P. Cerliani
Juan P. Cerliani
SVSilvia I. Vanzulli
Silvia I. Vanzulli
CPCecilia Pérez Piñero
Cecilia Pérez Piñero
MBMaría C. Bottino
María C. Bottino
ASAna Sahores
Ana Sahores
CLCaroline A. Lamb
Caroline A. Lamb

15 May 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
ASAna Sahores
Ana Sahores
GLGuillermina M. Luque
Guillermina M. Luque
VWVictoria Wargon
Victoria Wargon
MMMaría May
María May
AMAlfredo Molinolo
Alfredo Molinolo
CLCaroline A. Lamb
Caroline A. Lamb
The basic component of Silastic® glue (Dow Corning) used to prepare Silastic® pellets is polydimethylsiloxane. This compound is also present in other commercial adhesives such as FASTIX® (Akapol SA) that are available in any store for that category. In the present study we developed low cost, easy to prepare handmade steroid pellets (HMSP) by mixing 17β-estradiol, progesterone or other synthetic steroids with FASTIX® adhesive. We assessed serum levels of 17β-estradiol, progesterone, prolactin and luteinizing hormone in ovariectomized mice treated for 24 and 48 h or 7, 14 and 28 days with 20 µg or 5 mg of 17β-estradiol or 5 mg progesterone HMSP. We found a time dependent and significant increase in the levels of both natural hormones, and a downregulation of serum luteinizing hormone levels, while both 17β-estradiol doses increased serum prolactin. Uterine weights at sacrifice and histological examination of the uteri and the mammary glands correlated with estrogen or progestin action. Finally, we evaluated the biological effects of HMSP compared to commercial pellets or daily injections in the stimulation or inhibition of hormone dependent mammary tumor growth, and found that HMSP were as effective as the other methods of hormone administration. These data show that HMSP represent a useful, low cost, easily accessible method for administering steroids to mice.

16 January 2020 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
XGXimena García
Ximena García
AEAndrés Elía
Andrés Elía
LGLucrecia Galizzi
Lucrecia Galizzi
MMMaría May
María May
ESEunice Spengler
Eunice Spengler
CLCaroline A. Lamb
Caroline A. Lamb

28 June 2018 in Discover Oncology
Verified
Journal Article
Closed access
PDF file
ASAna Sahores
Ana Sahores
VFVirginia Figueroa
Virginia Figueroa
MMMaría May
María May
MLMarcos Liguori
Marcos Liguori
ARAdrián Rubstein
Adrián Rubstein
CLCaroline A. Lamb
Caroline A. Lamb